Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN stud... by Wood, G, Grenader, T, Nash, S, Adams, R, Kaplan, R, Fisher, D, Maughan, T, Bridgewater, J

Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/− cetuximab in oesophageal cancer by Crosby, T, Hurt, C, Falk, S, Gollins, S, Staffurth, J, Ray, R, Bridgewater, J, Geh, J, Cunningham, D, Blazeby, J, Roy, R, Maughan, T, Griffiths, G, Mukherjee, S

Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. by Crosby, T, Hurt, C, Falk, S, Gollins, S, Mukherjee, S, Staffurth, J, Ray, R, Bashir, N, Bridgewater, J, Geh, J, Cunningham, D, Blazeby, J, Roy, R, Maughan, T, Griffiths, G

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. by Mukherjee, S, Hurt, C, Bridgewater, J, Falk, S, Cummins, S, Wasan, H, Crosby, T, Jephcott, C, Roy, R, Radhakrishna, G, McDonald, A, Ray, R, Joseph, G, Staffurth, J, Abrams, R, Griffiths, G, Maughan, T

SCALOP-2: A randomised trial of induction GEMABX followed by chemoradiation (high/standard dose radiation) +/-nelfinavir for locally advanced pancreatic cancer: results of the dose... by Mukherjee, S, Virdee, P, Shaw, R, Bridgewater, J, Radhakrishna, G, Falk, S, Scott-Brown, M, Strauss, V, Brookes, C, Gillmore, R, Patel, N, Tranter, B, Parsons, P, Sebag-Montefiore, S, Hawkins, M, Corrie, P, Maughan, T

Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancre... by Strauss, V, Shaw, R, Virdee, P, Hurt, C, Ward, E, Tranter, B, Patel, N, Bridgewater, J, Parsons, P, Radhakrishna, G, O’Neill, E, Sebag-Montefiore, D, Hawkins, M, Corrie, P, Maughan, T, Mukherjee, S

A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan and Cic... by Middleton, G, Brown, S, Lowe, C, Maughan, T, Gwyther, S, Oliver, A, Richman, S, Blake, D, Napp, V, Marshall, H, Wadsley, J, Maisey, N, Chau, I, Hill, M, Gollins, S, Myint, S, Slater, S, Wagstaff, J, Bridgewater, J, Seymour, M

A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan and Cic... by Middleton, G, Brown, S, Lowe, C, Maughan, T, Gwyther, S, Oliver, A, Richman, S, Blake, D, Napp, V, Marshall, H, Wadsley, J, Maisey, N, Chau, I, Hill, M, Gollins, S, Myint, S, Slater, S, Wagstaff, J, Bridgewater, J, Seymour, M

SCALOP-2: A multi-centre randomised trial of induction chemotherapy followed by capecitabine +/-nelfinavir with high or standard dose radiotherapy for locally advanced pancreatic c... by Mukherjee, S, Virdee, P, Shaw, R, Bridgewater, J, Radhakrishna, G, Falk, S, Scott-Brown, M, Strauss, V, Brookes, C, Gillmore, R, Patel, N, Tranter, B, Parsons, P, Sebag-Montefiore, D, Hawkins, M, Corrie, P, Maughan, T

SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metas... by Virdee, P, Shaw, R, Strauss, V, Hamill, C, Hurt, C, Corrie, P, Bridgewater, J, Parsons, P, Tranter, B, Sebag-Montefiore, D, Chu, K, Radhakrishna, G, Hawkins, M, O'Neill, E, Campbell, S, Love, S, Maughan, T, Mukherjee, S

P-233: SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced no... by Virdee, P, Shaw, R, Strauss, V, Hamill, C, Hurt, C, Gwynne, S, Corrie, P, Bridgewater, J, Parsons, P, Tranter, B, Sebag-Montefiore, D, Chu, K, Radhakrishna, G, Hawkins, M, O'Neill, E, Campbell, S, Love, S, Maughan, T, Mukherjee, S

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. by Maughan, T, Adams, R, Smith, C, Meade, A, Seymour, M, Wilson, R, Idziaszczyk, S, Harris, R, Fisher, D, Kenny, S, Kay, E, Mitchell, J, Madi, A, Jasani, B, James, MD, Bridgewater, J, Kennedy, M, Claes, B, Lambrechts, D, Kaplan, R, Cheadle, J

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial by Iveson, T, Kerr, R, Saunders, M, Cassidy, J, Hollander, N, Tabernero, J, Haydon, A, Glimelius, B, Harkin, A, Allan, K, McQueen, J, Scudder, C, Boyd, K, Briggs, A, Waterston, A, Medley, L, Wilson, C, Ellis, R, Essapen, S, Dhadda, A, Harrison, M, Falk, S, Raouf, S, Rees, C, Olesen, R, Propper, D, Bridgewater, J, Azzabi, A, Farrugia, D, Webb, A, Cunningham, D, Hickish, T, Weaver, A, Gollins, S, Wasan, H, Paul, J